Ultrasound evaluation of valsartan therapy for renal cortical perfusion
Ultrasound evaluation of valsartan therapy for renal cortical perfusion
复制标题
DOI：
10.1291/hypres.27.345
复制
发表时间：
2004-05-01
影响因子：
5.4
通讯作者：
Iwasaka, T
中科院分区：
文献类型：
--
作者：
Kishimoto, N;Mori, Y;Iwasaka, T
在血管紧张素II受体阻滞剂治疗开始时，肾血流量的增加伴随着滤过分数的减少，已经被证明可以预测长期的肾脏保护效果。然而，在临床环境中观察到血管紧张素受体阻滞剂引起的肾皮质血流灌注改变的研究尚未见报道。我们最近开发了一种方便的方法，用对比增强的谐波超声评价人的肾皮质血流。本研究的目的是用这种方法检测血管紧张素II受体阻滞剂valsartan对肾皮质血流的影响。我们对7名健康志愿者进行了静脉注射微泡造影剂的间歇性二次谐波成像。口服Valsartan(80 Mg)后的超声造影显示微泡速度显著增加，这与用对氨基马尿酸清除法测定的肾总血流量的增加有很好的相关性(r=0.950，p<0.05)。
An increase in renal blood flow with a concomitant decrease in filtration fraction at the onset of angiotensin II receptor blocker treatment has been shown to predict a long-term renoprotective effect. However, no studies are available regarding angiotensin receptor blocker-induced changes in renal cortical perfusion observed in the clinical setting. We have recently developed a convenient method of evaluating human renal cortical blood flow with contrast-enhanced harmonic ultrasonography. The goal of this study was to use this method to examine the effect of valsartan, an angiotensin II receptor blocker, on renal cortical perfusion. We performed intermittent second harmonic imaging with venous infusion of a microbubble contrast agent in 7 healthy volunteers. Contrast-enhanced harmonic ultrasonography performed after oral administration of valsartan (80 mg) showed a significant increase in microbubble velocity, which correlated well with the increase in total renal blood flow determined by p-aminohippurate clearance (r=0.950, p